Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding). [clinicaltrials_resource:4263b24aac0c1797768ed96cc27583a5]
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding). [clinicaltrials_resource:4263b24aac0c1797768ed96cc27583a5]
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
Bio2RDF identifier
4263b24aac0c1797768ed96cc27583a5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4263b24aac0c1797768ed96cc27583a5
measure [clinicaltrials_vocabulary:measure]
Number of Participants With Fi ...... the Intended Treatment Period
time frame [clinicaltrials_vocabulary:time-frame]
Time to first event in "Intend ...... an-2011, prior to unblinding).
description
All suspected efficacy events ...... g, or other objective testing.
identifier
clinicaltrials_resource:4263b24aac0c1797768ed96cc27583a5
title
Number of Participants With Fi ...... an-2011, prior to unblinding).
@en
type
label
Number of Participants With Fi ...... 3b24aac0c1797768ed96cc27583a5]
@en